🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Eris Lifesciences Limited ERIS NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.eris.co.in
Company Profile ↓
₹1,452.40
-16.27% 1Y
Mkt Cap₹20,121.97 Cr
P/E32.09
P/B5.08
Div. Yield1.01%
52W High₹1,806.90
52W Low₹1,264.22
Book Value₹281.69
EPS (TTM)₹45.26

Company Overview

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 15.7%.

Consistent Profit Growth

Net profit has compounded at 17.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 23.3% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 32.1, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 19.9%.

Recent Developments

  • Mar 2026 Revenue of ₹3,114.89 Cr (+8.2% YoY); net profit ₹619.50 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +8.2%, earnings +76.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 23.3%, profit CAGR 17.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:23.30%
1 Year:8.18%

Compounded Profit Growth

5 Years:17.47%
1 Year:76.07%

Stock Price Performance

1 Year:-16.27%
6 Months:-6.03%
3 Months:+0.61%
1 Month:+4.91%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 35% of range
₹1,264.22 ₹1,806.90
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)56.95 · Neutral
Price Performance
1M+4.91%
3M+0.61%
6M-6.03%
1Y-16.27%
Valuation vs Sector

P/E of 32.09 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 23.3% over 5 years.
  • Profit CAGR of 17.5% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
32.09
Industry PE
39.97
Forward P/E
23.75
PEG Ratio
-
Book Value
₹281.69
Price to Book
5.08
P/S
6.45
EV/EBITDA
19.73
Dividend Yield
1.01%

Growth (CAGR)

Revenue 5Y
23.30%
Profit 5Y
17.47%
Revenue (YoY)
8.18%
Earnings (YoY)
76.07%

Profitability & Returns

ROCE
15.72%
ROE
15.87%
ROA
8.41%
Profit Margin
19.89%
Op Margin
26.99%
Gross Margin
74.46%
EPS (Latest Qtr)
₹20.57
EPS (TTM)
₹45.26

Balance Sheet & Liquidity

Debt/Equity
0.60
Quick Ratio
0.53
Current Ratio
0.74
Debt
₹2,358.62 Cr
Total Assets
₹7,365.51 Cr
Current Assets
₹1,539.85 Cr
Working Capital
₹-537.25 Cr

Ownership

Promoter Holding
69.69%
Chg in Prom Hold
-0.00%
FII / Inst Holding
22.76%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹20,121.97 Cr
Total Revenue (TTM)
₹3,114.89 Cr
EBITDA
₹1,110.71 Cr
Free Cash Flow
₹241.13 Cr
Operating Cash Flow
₹537.99 Cr
Shares Outstanding
₹13.85 Cr
Gross Margin
74.46%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ERIS Eris Lifesciences Limited NIFTY_SMALLNSEPHARMA 1,452.40 32.09 ₹20,121.97 Cr 1.01% 15.72% 15.87% 23.30% 17.47%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 403.00 Cr467.00 Cr505.00 Cr486.00 Cr551.00 Cr720.00 Cr741.00 Cr-702.60 Cr771.56 Cr790.15 Cr800.89 Cr752.29 Cr
Cost of Revenue --------170.25 Cr184.64 Cr202.41 Cr223.30 Cr185.25 Cr
Gross Profit --------532.35 Cr586.92 Cr587.74 Cr577.59 Cr567.04 Cr
Operating Expenses 284.00 Cr297.00 Cr324.00 Cr311.00 Cr402.00 Cr470.00 Cr477.00 Cr-357.16 Cr380.72 Cr368.61 Cr366.32 Cr362.95 Cr
Operating Income 84.00 Cr129.00 Cr139.00 Cr130.00 Cr94.00 Cr174.00 Cr185.00 Cr-175.19 Cr206.20 Cr219.13 Cr211.27 Cr204.09 Cr
EBITDA 119.00 Cr170.00 Cr181.00 Cr176.00 Cr148.00 Cr250.00 Cr265.00 Cr-260.35 Cr280.29 Cr291.30 Cr264.51 Cr274.60 Cr
Interest Expense 9.00 Cr17.00 Cr16.00 Cr18.00 Cr33.00 Cr60.00 Cr59.00 Cr-54.28 Cr48.68 Cr49.55 Cr48.82 Cr45.62 Cr
Pretax Income 76.00 Cr112.00 Cr126.00 Cr116.00 Cr77.00 Cr116.00 Cr129.00 Cr-128.87 Cr161.10 Cr172.67 Cr145.35 Cr159.41 Cr
Tax Provision 14.44 Cr19.04 Cr3.78 Cr13.92 Cr-3.08 Cr25.52 Cr32.25 Cr-26.52 Cr36.00 Cr38.20 Cr36.52 Cr-119.69 Cr
Net Income 61.00 Cr94.00 Cr122.00 Cr101.00 Cr80.00 Cr90.00 Cr96.00 Cr-93.84 Cr117.99 Cr120.19 Cr99.72 Cr281.61 Cr
Diluted EPS 4.816.989.077.555.226.126.73-6.898.648.817.3220.57

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 546.00 Cr597.00 Cr750.00 Cr856.00 Cr982.00 Cr1,074.00 Cr1,212.00 Cr-1,661.82 Cr1,991.30 Cr2,879.26 Cr3,114.89 Cr
Cost of Revenue --------357.08 Cr387.64 Cr713.99 Cr795.60 Cr
Gross Profit --------1,304.74 Cr1,603.66 Cr2,165.27 Cr2,319.29 Cr
Operating Expenses 427.00 Cr425.00 Cr480.00 Cr533.00 Cr637.00 Cr702.00 Cr781.00 Cr-882.55 Cr1,108.25 Cr1,463.53 Cr1,478.71 Cr
Operating Income 102.00 Cr152.00 Cr246.00 Cr296.00 Cr309.00 Cr322.00 Cr388.00 Cr-422.19 Cr495.41 Cr701.74 Cr840.58 Cr
EBITDA 118.00 Cr172.00 Cr269.00 Cr322.00 Cr345.00 Cr372.00 Cr431.00 Cr-547.90 Cr698.65 Cr1,035.62 Cr1,110.71 Cr
Interest Expense 001.00 Cr11.00 Cr23.00 Cr2.00 Cr2.00 Cr-26.17 Cr84.80 Cr231.29 Cr192.67 Cr
Pretax Income 109.00 Cr154.00 Cr270.00 Cr312.00 Cr317.00 Cr331.00 Cr394.00 Cr-404.64 Cr431.34 Cr488.87 Cr638.54 Cr
Tax Provision 19.62 Cr20.02 Cr24.30 Cr18.72 Cr25.36 Cr36.41 Cr39.40 Cr-30.48 Cr34.22 Cr114.20 Cr-8.97 Cr
Net Income 89.00 Cr135.00 Cr247.00 Cr295.00 Cr291.00 Cr297.00 Cr355.00 Cr-382.16 Cr392.05 Cr351.84 Cr619.50 Cr
Diluted EPS 6,489.459,714.1817.9521.3921.1521.8426.16-28.0728.7925.8145.26

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 357.00 Cr397.00 Cr692.00 Cr1,408.00 Cr1,502.00 Cr1,502.00 Cr1,785.00 Cr-3,667.33 Cr7,040.46 Cr7,033.17 Cr7,365.51 Cr
Current Assets --------764.72 Cr2,302.04 Cr1,222.99 Cr1,539.85 Cr
Cash & Equivalents --------55.95 Cr94.14 Cr199.64 Cr54.74 Cr
Inventory --------131.44 Cr189.03 Cr334.83 Cr436.82 Cr
Receivables --------292.71 Cr422.03 Cr458.64 Cr680.34 Cr
Total Liabilities --------1,446.65 Cr3,818.37 Cr3,761.41 Cr3,469.85 Cr
Current Liabilities --------443.23 Cr2,532.07 Cr1,381.39 Cr2,077.10 Cr
Long Term Debt --------644.45 Cr654.51 Cr1,737.51 Cr955.83 Cr
Total Debt 1.00 Cr01.00 Cr377.00 Cr176.00 Cr07.00 Cr-876.71 Cr2,781.28 Cr2,477.92 Cr2,358.62 Cr
Total Equity 266.14 Cr299.14 Cr567.00 Cr862.00 Cr1,151.00 Cr1,297.00 Cr1,577.00 Cr-2,195.99 Cr2,586.18 Cr2,854.36 Cr3,902.67 Cr
Shares Outstanding --------13.60 Cr13.60 Cr13.62 Cr13.85 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 90.00 Cr131.00 Cr200.00 Cr235.00 Cr223.00 Cr271.00 Cr375.00 Cr-291.74 Cr486.01 Cr1,065.01 Cr537.99 Cr
Investing Cash Flow -92.00 Cr-44.00 Cr-184.00 Cr-590.00 Cr-5.00 Cr123.00 Cr-323.00 Cr--982.10 Cr-1,854.52 Cr-79.97 Cr-369.46 Cr
Financing Cash Flow 0-84.00 Cr-24.00 Cr363.00 Cr-221.00 Cr-335.00 Cr-82.00 Cr-688.02 Cr1,379.78 Cr-881.32 Cr-313.53 Cr
Capital Expenditure -13.00 Cr-23.00 Cr-50.00 Cr-25.00 Cr-37.00 Cr-146.00 Cr-25.00 Cr--841.42 Cr-129.16 Cr-155.00 Cr-296.86 Cr
Free Cash Flow 77.00 Cr108.00 Cr150.00 Cr210.00 Cr186.00 Cr125.00 Cr350.00 Cr--549.68 Cr356.85 Cr910.01 Cr241.13 Cr
Net Change in Cash -2.00 Cr4.00 Cr-8.00 Cr8.00 Cr-3.00 Cr60.00 Cr-30.00 Cr--2.34 Cr11.27 Cr103.72 Cr-145.00 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------78.5%80.5%75.2%74.5%
Operating Margin % 18.7%25.5%32.8%34.6%31.5%30.0%32.0%-25.4%24.9%24.4%27.0%
Net Margin % 16.3%22.6%32.9%34.5%29.6%27.7%29.3%-23.0%19.7%12.2%19.9%
ROE % 33.4%45.1%43.6%34.2%25.3%22.9%22.5%-17.4%15.2%12.3%15.9%
ROCE % --------13.1%11.0%12.4%15.9%

Shareholding Pattern

Insiders
69.69%
Institutions
22.76%
Public Float
75.11%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ERIS

Google News ue, 14 Apr 2026

New CME options target hedging U.S. rate swings from June 16 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQVTRGNHU5SHlPTTJRQ1IxWG9BUEhyeWRRX3NocV93MzRobF8tdU9Bb0VhSzNZTUl2VXFFdzg2eHpJNXQ4SjdTaUEzbFl3WlZTZEJvaUUwU0R5SzZmcU1BSDZpUHdnOVNBdVN0TTJfd25Dd1BBVlNkMkhlRWZ0a0NiR1p5SGhuTHVIWDM4eW…

Google News Fri, 26 Jun 2026

Eris Lifesciences Ltd Actuals & Estimates (NSE:ERIS) - TradingView

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxORU1qdmk2a29ZZDA1b2paVkRzV2tlWmg4dGxJa191ZkJZeDVNZGNRYThVVXNvQ2xzbmp4Uzh5TVp0anZQempUMkNhYjJQNkpzVnhCUU1KQmVaa1V2bGVFTmo2WXJObEJuMlNsdmZGemhCS3luQ0xlRUE2TGRBNXBVMldB?oc=5" target=…

Google News hu, 21 May 2026

Here's Why Eris Lifesciences (NSE:ERIS) Has Caught The Eye Of Investors - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOUnF5OGJmT2t4M3h5QnNnZENzWUJickNzZFFBNWNkbFBoc2YxVnN5WXdKRVpUZjByRVhNemMxWm5MVVo1NXB3R2tVT1VOMkF6c2tMVnRqa2ZiVXFwUE8zUU9XMVdDNmJqRF9mcVRnN25PMk13UEJxdG52eVdJaEsxYkhnaGdwSHQ5TjZBOU…

Google News ue, 21 Apr 2026

Eris Lifesciences shares decline nearly 6% after observations issued for Swiss facilities - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOU2FCLUwtU2d1QWctUUNjbk9HN2p3MUNTUnlKeDl3TTR2UVFxWE15WDVINjBSQ0sxR045TDVNREVVVFZzZTd4dnc5a0hNMk5FRi1FcGdnUnZMZlZfUzBpaUotLUx2LVFMaUlNZDF0VDF1NElZcW5NQkxNa0RpYVZSXzlJT0pyV19xcWFxRE…

Google News Wed, 20 May 2026

Eris Lifesciences Q4 profit jumps three-fold to ₹281.6 cr; shares surge 11% - Business Standard

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPV01McG9tdFlyX2dIUk1sMkFJV0syN0p6ZzFTcUJHWGg1ZDVSVFhPZGsyM1pYcXp4NkRQUG5qMGU0c2w1dEc0V1d1XzRrenN4dnE1T0NJM3hKLV80Y25HVzJtQVpBSVQweTFxU1drRUthQ01wQ2NFNWZpbk5sNERHVWUtNHFnREc3SnBldF…

Google News Wed, 20 May 2026

Earnings call transcript: Eris Lifesciences Q4 2026 sees strong domestic growth By Investing.com - Investing.com India

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNcTR2STFZSHR1TFh1UDc4dzRBWlpEZUtIcVNrWlFvOXRRbjVZM1RVX2FON2hFd25yRjZYbVVlMFRhaGJJbnJ1dEZJXzZBQ1FQRW56SGxfSTVMa1FQQ2hqMjlSZGxHc3VlcUU1cGNvSkdwZ2JwWDk4OTdvSmR3MTB0MDRkNXp5cUV3bjhQME…

ERIS — Frequently Asked Questions

What is the current share price of Eris Lifesciences Limited (ERIS)?

As of 2026-07-15 09:52 IST, Eris Lifesciences Limited (ERIS) trades at ₹1,452.40 on NSE. Its 52-week range is ₹1,264.22 to ₹1,806.90.

What is the market capitalisation of ERIS?

Eris Lifesciences Limited (ERIS) has a market capitalisation of ₹20,121.97 Cr on NSE.

What is the P/E ratio of ERIS?

ERIS trades at a trailing price-to-earnings (P/E) ratio of 32.09. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.08.

Does ERIS pay a dividend?

Eris Lifesciences Limited (ERIS) currently offers a dividend yield of 1.01%.

What is the return on equity (ROE) of ERIS?

ERIS has a return on equity (ROE) of 15.87%. Its return on capital employed (ROCE) is 15.72%.

Is ERIS a good stock to buy?

This page provides a data-driven analysis of Eris Lifesciences Limited (ERIS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space